537 related articles for article (PubMed ID: 31148900)
1. Mechanisms of hepatocellular carcinoma progression.
Ogunwobi OO; Harricharran T; Huaman J; Galuza A; Odumuwagun O; Tan Y; Ma GX; Nguyen MT
World J Gastroenterol; 2019 May; 25(19):2279-2293. PubMed ID: 31148900
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
3. Impaired function of CD4+ T follicular helper (Tfh) cells associated with hepatocellular carcinoma progression.
Jia Y; Zeng Z; Li Y; Li Z; Jin L; Zhang Z; Wang L; Wang FS
PLoS One; 2015; 10(2):e0117458. PubMed ID: 25689070
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma.
Long J; Wang A; Bai Y; Lin J; Yang X; Wang D; Yang X; Jiang Y; Zhao H
EBioMedicine; 2019 Apr; 42():363-374. PubMed ID: 30885723
[TBL] [Abstract][Full Text] [Related]
6. IL-37b suppresses epithelial mesenchymal transition in hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling.
Pu XY; Zheng DF; Shen A; Gu HT; Wei XF; Mou T; Zhang JB; Liu R
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):408-415. PubMed ID: 30201411
[TBL] [Abstract][Full Text] [Related]
7. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
8. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in the Wnt/β-catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular carcinoma.
Kim SS; Cho HJ; Lee HY; Park JH; Noh CK; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
Clin Biochem; 2016 Jul; 49(10-11):792-801. PubMed ID: 26968103
[TBL] [Abstract][Full Text] [Related]
10. [Hepatocellular carcinoma].
Semela D; Heim M
Ther Umsch; 2011 Apr; 68(4):213-7. PubMed ID: 21452143
[TBL] [Abstract][Full Text] [Related]
11. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.
Hernandez-Gea V; Toffanin S; Friedman SL; Llovet JM
Gastroenterology; 2013 Mar; 144(3):512-27. PubMed ID: 23313965
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics Analysis Reveals Distinct Molecular Characteristics of Hepatitis B-Related Hepatocellular Carcinomas from Very Early to Advanced Barcelona Clinic Liver Cancer Stages.
Kong FY; Wei X; Zhou K; Hu W; Kou YB; You HJ; Liu XM; Zheng KY; Tang RX
PLoS One; 2016; 11(7):e0158286. PubMed ID: 27454179
[TBL] [Abstract][Full Text] [Related]
13. Alcohol and hepatocellular carcinoma: a review and a point of view.
Testino G; Leone S; Borro P
World J Gastroenterol; 2014 Nov; 20(43):15943-54. PubMed ID: 25473148
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of hepatocellular carcinoma contributes to cancer progression.
Jeng KS; Chang CF; Jeng WJ; Sheen IS; Jeng CJ
Crit Rev Oncol Hematol; 2015 Jun; 94(3):337-47. PubMed ID: 25680939
[TBL] [Abstract][Full Text] [Related]
15. Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy.
Yin Z; Jiang K; Li R; Dong C; Wang L
Mol Cancer; 2018 Dec; 17(1):178. PubMed ID: 30593276
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway.
Li Y; Liu G; Li X; Dong H; Xiao W; Lu S
Biochem Biophys Res Commun; 2018 Sep; 503(4):2826-2832. PubMed ID: 30115383
[TBL] [Abstract][Full Text] [Related]
17. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapies for hepatocellular carcinoma.
Ge S; Huang D
Drug Discov Ther; 2015 Oct; 9(5):352-62. PubMed ID: 26632544
[TBL] [Abstract][Full Text] [Related]
19. [Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].
Petry W; Heintges T; Hensel F; Erhardt A; Wenning M; Niederau C; Häussinger D
Z Gastroenterol; 1997 Dec; 35(12):1059-67. PubMed ID: 9487638
[TBL] [Abstract][Full Text] [Related]
20. Role of the microenvironment in hepatocellular carcinoma development and progression.
Wu SD; Ma YS; Fang Y; Liu LL; Fu D; Shen XZ
Cancer Treat Rev; 2012 May; 38(3):218-25. PubMed ID: 21763074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
